The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Mineralys Therapeutics Inc (NASDAQ: MLYS) closed at $40.46 in the last session, up 1.63% from day before closing price of $39.81. In other words, the price has increased by $1.63 from its previous closing price. On the day, 0.65 million shares were traded. MLYS stock price reached its highest trading level at $40.47 during the session, while it also had its lowest trading level at $38.71.
Ratios:
We take a closer look at MLYS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 15 ’25 when Rodman David Malcom sold 11,367 shares for $36.00 per share. The transaction valued at 409,266 led to the insider holds 81,524 shares of the business.
Rodman David Malcom bought 11,367 shares of MLYS for $409,266 on Sep 15 ’25. On Sep 04 ’25, another insider, AKKARAJU SRINIVAS, who serves as the Director of the company, bought 588,235 shares for $25.50 each. As a result, the insider paid 14,999,992 and bolstered with 588,235 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 3138469888 and an Enterprise Value of 2357387264.
Stock Price History:
The Beta on a monthly basis for MLYS is 0.40, which has changed by 1.9149857 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $41.09, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 63.37%, while the 200-Day Moving Average is calculated to be 152.82%.
Shares Statistics:
According to the various share statistics, MLYS traded on average about 1.51M shares per day over the past 3-months and 1570360 shares per day over the past 10 days. A total of 65.73M shares are outstanding, with a floating share count of 50.57M. Insiders hold about 34.81% of the company’s shares, while institutions hold 64.66% stake in the company. Shares short for MLYS as of 1757894400 were 7579857 with a Short Ratio of 5.01, compared to 1755216000 on 7408973. Therefore, it implies a Short% of Shares Outstanding of 7579857 and a Short% of Float of 12.280000000000001.
Earnings Estimates
Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of Mineralys Therapeutics Inc (MLYS) in the stock market.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.48 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.35 and -$3.44 for the fiscal current year, implying an average EPS of -$2.72. EPS for the following year is -$2.65, with 7.0 analysts recommending between -$1.89 and -$3.43.
